Table 1 Individual patients characteristics
Individual number | Sex | Age | Duration of AF (years) | CHD | LA volume (ml) | AA drug treatment before PVI | Duration of radiofrequency impulses (seconds) | Relapse | AA Drug treatment after PVI |
|---|---|---|---|---|---|---|---|---|---|
1 | F | 51 | 2 | One vessel CHD | 99 | Sotalol | 56 | Yes, re-PVI | Sotalol |
2 | M | 55 | 10 | No CHD | 122 | Beta blocker | 41 | Yes, re-PVI | Beta blocker |
3 | F | 67 | 7 | No CHD | 123 | Beta blocker, dronedarone | 61 | Yes, re-PVI | Beta blocker, dronedarone |
4 | M | 44 | 13 | No CHD | 72 | Beta blocker | 40 | None | Beta blocker, flecainide |
5 | F | 56 | 4 | No CHD | 118 | Beta blocker, flecainide | 79 | None | Beta blocker, flecainide |
6 | M | 54 | 1 | No CHD | 76 | Beta blocker, flecainide | 61 | None | Beta blocker, flecainide |
7 | M | 72 | 17 | No CHD | 82 | Beta blocker, dronedarone | 69 | None | Beta blocker, dronedarone |
8 | M | 69 | 3 | three vessel CHD | 183 | Beta blocker | 98 | Yes, re-PVI | Beta blocker, dronedarone |
9 | M | 64 | 2 | No CHD | 125 | Beta blocker, flecainide | 91 | None | Beta blocker, propafenone |
10 | F | 49 | 5 | No CHD | 82 | Beta blocker, flecainide | 81 | None | Beta blocker, flecainide |
11 | M | 48 | 1 | No CHD | 116 | Beta blocker, dronedarone | 43 | None | Dronedarone |
12 | F | 70 | 2 | No CHD | N/A | Beta blocker, dronedarone | 40 | Yes, no re-PVI | Beta blocker, flecainide |
13 | M | 52 | 5 | No CHD | 103 | Beta blocker, flecainide | 33 | None | Beta blocker, flecainide |
14 | M | 40 | 1 | No CHD | 52 | Beta blocker | 41 | None | Beta blocker, flecainide |
15 | M | 61 | 4 | No CHD | 115 | Beta blocker, flecainide | 49 | None | Beta blocker, flecainide |
16 | M | 52 | 5 | No CHD | 103 | Beta blocker, flecainide | 51 | None | Beta blocker, flecainide |